You might also like...
Check out some other posts from Augusta University
Stephen Hsu, PhD, a professor at the Dental College of Georgia at Augusta University, unveiled his groundbreaking nanotechnology, known as FAST, during a keynote address at the 8th World Congress on Infectious Diseases in Rome, Italy.
FAST, or Facilitated Self-Assembling Technology, offers a revolutionary way to convert compounds that are difficult to dissolve in water into stable nanoparticles. This innovation could transform drug development, viral infection prevention, hospital hygiene and more.
“FAST takes a completely different approach from traditional nanotechnology,” Hsu explained. “Unlike methods that rely on polymers, metals, surfactants, fat-based carriers or complex engineering processes, FAST allows compounds to self-assemble into nanoparticles with minimal effort. This makes drugs that were once nearly impossible to formulate in water stable, effective and practical for medical and consumer use.” At the heart of this innovation is EC16, or EGCG-palmitate, a lipid-soluble compound derived from green tea. Known for its antioxidant, anticancer, anti-inflammatory and antimicrobial properties, green tea has long been studied but is challenging to use in clinical settings due to stability issues. FAST overcomes these limitations, transforming EC16 and other hydrophobic compounds into water-friendly nanoparticles.
“You can’t even tell the particles are there,” said Hsu. “They look just like water. I made several different formulations in one afternoon in my lab. It’s that fast and simple.” A natural solution to global challenges Hsu’s work is the culmination of decades of research and a deeply personal journey. He credits green tea with helping him survive illness during his youth in a labor camp in China. Now, he’s turning its natural properties into cutting-edge therapies with the hope of helping more people.
“I’ve been drinking green tea my entire life,” Hsu said. “Now, we’re turning its benefits into medical-grade treatments.” Supported by over $600,000 in NIH grants, Hsu’s team is developing applications like alcohol-free disinfectants and nasal sprays to prevent respiratory virus infections. One promising product is an EC16-based disinfectant that is natural, non-toxic and highly effective against tough pathogens, like norovirus and C. difficile, a bacterium that can cause severe diarrhea.
“That’s a big deal for schools, hospitals and places like cruise ships, where these infections spread easily,” he said. Tackling long COVID and beyond Among FAST’s most promising applications is a nasal spray developed to prevent or treat long COVID and other respiratory illnesses. The spray, currently undergoing preclinical testing, targets viral entry points in the nasal mucosa, where infections often begin.
“Our goal is to help immunocompromised patients and those with lingering symptoms like brain fog and loss of smell,” Hsu said. “We’ve already seen strong in vitro results against human coronavirus and norovirus.” In addition to nasal and topical treatments, Hsu’s team has developed oral formulations of EC16 that remain stable through the stomach’s acidic environment, critical for treating gastrointestinal viruses and potentially inflammatory bowel diseases like Crohn’s.
“We found that even without direct contact with the virus, the EC16 nanoparticles taken by mouth can reduce infection,” Hsu explained. “That’s a major step forward in treatment of digestive tract viral infections.” A platform for the future of medicine FAST isn’t limited to green tea compounds. Hsu’s method can transform a wide range of hydrophobic compounds like cannabidiol, ivermectin, quercetin, procyanidin and retinoic acid, as well as hundreds of existing drugs, into nanoparticle suspensions that are stable and water-friendly.
This has huge implications,” said Hsu. “Up to 90% of new drug candidates have poor water solubility and low bioavailability, which limits their effectiveness. With FAST, we can change that.” His lab is already exploring applications in Alzheimer’s research, cancer therapy, oral health and even anti-biofilm coatings to prevent hospital infections. These products, along with the nasal spray, are expected to hit the market this fall.
Hsu is currently finalizing publications and preparing patent filings to protect and expand the reach of FAST. While optimistic, he remains cautious.
“The results so far are phenomenal. FAST could be a new chapter in how we fight disease and deliver medicine,” Hsu said. Looking to know more about FAST nanotechnology and the research happening at Augusta University?
To connect with Dr. Stephen Hsu - simply contact AU's External Communications Team mediarelations@augusta.edu to arrange an interview today.
Jennifer C. Sullivan, PhD, dean of The Graduate School at Augusta University, has dedicated her research to better understand why blood pressure increases in hypertension and raising awareness to the dangers of not paying attention to heart health, particularly among women.
Throughout her career, Sullivan has been continuously funded by the National Institutes of Health (NIH) and the American Heart Association since becoming a tenure-track faculty member in 2008, and now she has a chance to take her research further after securing a five-year, $7.5 million grant to have Augusta University designated as a Specialized Center of Research Excellence on Sex Differences (SCORE) by the NIH’s Office of Research on Women’s Health. It’s a distinction that places AU among 10 other leaders in research for the field, including Brigham and Women’s Hospital, Cedars-Sinai Medical Center, Emory University, Johns Hopkins University, Massachusetts General Hospital and Harvard Medical School, the Mayo Clinic, the Medical University of South Carolina, the University of Colorado and Yale University. The University of California, Los Angeles has two SCORE programs.
“I’m so proud and excited for this opportunity because this has been what I have focused my research program on for my entire career, and to be able to advance it with a program like this, where we can actually build a unique program focused on an area that can make a difference, is just so much fun,” Sullivan said. “Just the fact that Augusta will be included on this list, attached to an organization of the caliber of NIH, will provide opportunities that we’ve never had before, especially for our students and younger researchers.” Sullivan’s SCORE project, “Improving awareness of women with hypertension: ROAR (Rural, Obese, At Risk),” focuses primarily on the fact that, while young women are considered “protected” from hypertension and the associated cardiovascular risk relative to age-matched men, the elimination of hypertension is projected to have a larger impact on cardiovascular disease (CVD) mortality in women.
“The group of people with the highest risk of death from hypertension is in the rural South of the U.S., specifically Black women are particularly vulnerable to developing hypertension and CVD,” Sullivan said. According to Sullivan’s research and information available from the American Heart Association (AHA), approximately 19 million deaths were attributed to CVD globally in 2020, an increase of about 20% from 2010. Both Sullivan and the AHA state that cardiovascular disease remains the leading cause of death for both men and women in the United States, and that hypertension is a major modifiable risk factor for CVD.
Sullivan said, “It has been suggested that eliminating hypertension would reduce CVD mortality by over 30% in men and 38% in women, but a critical barrier to limiting premature death from CVD is lack of awareness surrounding the risks of CVD. Our overall goal in this new funded project is to transform academic and community understanding of sex as a biological variable in the consideration of hypertension.”
The three research projects include Sullivan’s lead project on high fat diets, a project on systemic lupus erythematosus (SLE) disproportionately affects young women led by Erin Taylor, PhD, at the University of Mississippi Medical Center, and another project looking at the role of inflammation and how immune cells are activated in SLE led by Michael Ryan, PhD, at the University of South Carlina’s School of Medicine.
But there is more to SCORE than just conducting research. Each SCORE team is also responsible for a career enhancement core and a leadership administrative core.
“What really sets these grants apart are the emphasis on the career enhancement and leadership administrative cores. The Career Enhancement Core is designed to be a bit open ended for each SCORE, but in talking to the NIH, what they were most excited about in our project is the community outreach piece we designed. “Our grant includes people across the entire campus, including Augusta University’s Medical College of Georgia, the College of Allied Health Sciences, the College of Education and Human Development and multiple campus partners including some of our sororities on campus and the Center for Writing Excellence,” Sullivan said. “More specifically, the COEHD is able to extend our outreach efforts to our local schools to begin educating children on the importance of screening, and our sororities are obviously connected with other chapters across the southeast which helps us spread our message, as well.” Sullivan notes that, through this portion of the project alone, there will be numerous opportunities to include students from Augusta University’s CAHS, College of Nursing, Department of Kinesiology, the Biomedical Sciences PhD program and the proposed School of Public Health. Marlo Vernon, PhD, associate professor at MCG and researcher for the Georgia Cancer Center, and Amanda Behr, chair of the Medical Illustration Program in CAHS, are also involved in various stages of the project.
“The other thing the Career Enhancement Core will do is provide pilot grants to three research projects each year for early-stage investigators. We’ll also be able to fund sabbaticals for graduate students or postdocs to go someplace else and learn cutting edge techniques from other experts, so there is a lot built in that will help us support up-and-coming researchers,” Sullivan said. “We’re now part of this consortium, and they have a once-a-year, in-person meeting at the NIH offices, so we’ll go to that for the first time this year, and what’s neat about it is they’re really promoting young investigators. Each grant can bring up to eight people, the our hope is that we will have the investigators funded by the pilot projects attend next year, giving those folks the opportunity to present and talk to program officers with the NIH and develop a pipeline of investigators committed to studying women’s health and sex as a biological variable.” Sullivan is also looking to designate some of her summer graduate and undergraduate research positions to the project beginning next summer.
“The Graduate School already has a summer program to support undergraduates that we will be able to piggyback off of. We have set aside five slots in that program for this that will go to students studying the sex as a biological variable, and the applications for that program, STAR, is already open,” Sullivan said. “We’re also planning a symposium in collaboration with the Physiology Department in April 2024. This is an annual event sponsored by the department, and this year they selected sex differences as the topic, so we are hoping to help increase exposure and attendance.” Looking to know more about the amazing research happening at Augusta?
To connect with Jennifer Sullivan, simply click on her icon ow to arrange an interview today.
A research team at Augusta University, led by Jennifer C. Sullivan, PhD, has secured a $4.4 million grant from the American Heart Association to study the risk factors for cardiovascular and kidney diseases and how they impact women.
Sullivan’s research center, “Disruptions in cardiorenal free fatty acid metabolism in Cardiovascular Kidney Metabolic Syndrome,” is part of a larger $15 million project titled “Strategically Focused Research Network on Cardiovascular Kidney Metabolic Syndrome: Heterogeneity in Women.” The overarching AHA project is aimed at learning why women may be more likely to develop cardiovascular and kidney diseases due to certain unique risk factors and life stages. Research teams from Massachusetts General Hospital and The Ohio State University were also chosen.
“I think this is a huge step for Augusta University as we continue to distinguish ourselves and the research that we have here focused on the health of women,” said Sullivan, dean of The Graduate School. “This grant is particularly impactful as we look to advance and improve the health of women, not just in Georgia, but for the entire country.” According to the Healthy Georgia Report, produced by AU’s School of Public Health, Georgia has the 23rd highest rate of obesity in the United States. Among the women living in the state, 38.3% of them, as well as 37.5% of people living in rural areas, suffer from obesity.
“It’s great that we are able to represent the state of Georgia because our state has such a high prevalence for obesity rates,” said Sullivan, who is the director of AU’s SCORE project “Improving awareness of women with hypertension: ROAR (Rural, Obese, At Risk).” “It’s important for us to understand that different populations have distinct needs. You can’t talk about a one-size-fits-all approach to health. This is really about trying to understand how different groups are impacted.” Each center is comprised of three teams, as well as a training component and an area partner. Together, they will explore obesity’s lifetime impact on CKM syndrome through three projects.
CKM syndrome is a clinical term that describes the combined health effects of heart disease, kidney disease, diabetes and obesity, which puts people at high risk for heart attack, stroke and heart failure. According to the American Heart Association’s 2025 Heart Disease and Stroke Statistics, about 1 in 3 U.S. adults has at least three components of CKM syndrome, which include high blood pressure, abnormal cholesterol, high blood glucose (sugar), impaired kidney function and excess body weight.
The first project is led by Daria Ilatovskaya, PhD, and Justine Abais-Battad, PhD, and will look at aging and Western diet-induced CKMS mechanisms in obesity. Ilatovskaya is an associate professor and the graduate program director for the Doctor of Philosophy in Physiology program, and Abais-Battad is an assistant professor in the Department of Physiology with the Medical College of Georgia at Augusta University.
The second component, led by Jessica Faulkner, PhD, an assistant professor in MCG’s Physiology department, will study obesity-associated mechanisms of CKMS in pregnancy.
The third project, led by Stephen Coughlin, PhD, with Marlo Vernon, PhD, is looking at CKMS epidemiology, associations with obesity, CVD/CKD. Coughlin is the program director for the Master of Science in Epidemiology and professor of epidemiology in the School of Public Health’s Department of Biostatistics, Data Science, and Epidemiology, while Vernon is an associate professor with MCG’s Georgia Prevention Institute and SPH’s Department of Community and Behavioral Health Sciences.
Additionally, the team will talk to women and health care providers from a variety of backgrounds and experiences to assess current knowledge and interest levels in heart health and use that information to develop programs that may help treat and prevent disease.
There is also a training director, Alison Kriegel, PhD, a professor in the Department of Physiology, and a core director, Guido Verbeck, PhD, chair and professor of the Department of Chemistry and Biochemistry in the College of Science and Mathematics. “We have a strong blend of clinical epidemiology and basic science, as well as a training component, which we will fill with post-doctoral fellows,” Sullivan said. “Dr. Ilatovskaya, Dr. Faulkner, Dr. Abais-Battad and Dr. Vernon are all a part of our ROAR grant, and, while this isn’t directly related to that program, it allowed us to demonstrate how we are already well positioned to work together to amplify our ability and increase awareness about the importance of the health of women.” The team has over 50 collaborative papers and has secured more than $13 million in collaborative funding to advance the health of women. They also all have experience training fellows and students to continue to expand their reach.
“We already have a lot of the infrastructure in place for this kind of cross-disciplinary project, so we leaned very heavily into our connections and the expertise we have here at Augusta University. It’s set up very similar to our ROAR program, so this is something that was really organic in nature,” Sullivan said. The American Heart Association has invested almost $300 million to establish 18 Strategically Focused Research Networks, each aimed at addressing a key strategic issue identified by the association’s volunteer Board of Directors. Prior networks have been studying a wide variety of important topics including, but not limited to, prevention, hypertension, the health of women, heart failure, obesity, vascular disease, atrial fibrillation, arrhythmias/sudden cardiac death, cardiometabolic health/type 2 diabetes, health technology, cardio-oncology, the biological impact of chronic psychosocial stress and the role of inflammation in cardiovascular health.
Each network centers around scientific knowledge and knowledge gaps, prevention, diagnosis and treatment of the key research topic. Three to six research centers make up each network, bringing together investigators with expertise in basic, clinical and population/behavioral health science to find new ways to diagnose, treat and prevent heart disease and stroke.
Funding scientific research and discovery through initiatives like these awards is a cornerstone of the century-old American Heart Association’s lifesaving mission. The association has now funded more than $5.9 billion in cardiovascular, cerebrovascular and brain health research since 1949, making it the single largest non-government supporter of heart and brain health research in the United States. New knowledge resulting from this funding continues to save lives and directly impact millions of people in every corner of the U.S. and around the world.
Looking to know more about the amazing research happening at Augusta?
To connect with Dr. Sullivan, simply click on her icon to arrange an interview today.
